IMOH...XXII is not a true biotech stock. Its a hybrid. It will have a basic "staples" business with or without FDA, which can flourish elsewhere (outside the U.S.) and quite handsomely.
The biotech aspect is the FDA designation as VLN...which is just a bonus.